A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding

Antibody treatment is currently the only available countermeasure for botulism, a fatal illness caused by flaccid paralysis of muscles due to botulinum neurotoxin (BoNT) intoxication. Among the seven major serotypes of BoNT/A-G, BoNT/A poses the most serious threat to humans because of its high pote...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 7; no. 1; pp. 7438 - 12
Main Authors: Yao, Guorui, Lam, Kwok-ho, Weisemann, Jasmin, Peng, Lisheng, Krez, Nadja, Perry, Kay, Shoemaker, Charles B., Dong, Min, Rummel, Andreas, Jin, Rongsheng
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 07-08-2017
Nature Publishing Group
Nature Portfolio
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibody treatment is currently the only available countermeasure for botulism, a fatal illness caused by flaccid paralysis of muscles due to botulinum neurotoxin (BoNT) intoxication. Among the seven major serotypes of BoNT/A-G, BoNT/A poses the most serious threat to humans because of its high potency and long duration of action. Prior to entering neurons and blocking neurotransmitter release, BoNT/A recognizes motoneurons via a dual-receptor binding process in which it engages both the neuron surface polysialoganglioside (PSG) and synaptic vesicle glycoprotein 2 (SV2). Previously, we identified a potent neutralizing antitoxin against BoNT/A1 termed ciA-C2, derived from a camelid heavy-chain-only antibody (VHH). In this study, we demonstrate that ciA-C2 prevents BoNT/A1 intoxication by inhibiting its binding to neuronal receptor SV2. Furthermore, we determined the crystal structure of ciA-C2 in complex with the receptor-binding domain of BoNT/A1 (H C A1) at 1.68 Å resolution. The structure revealed that ciA-C2 partially occupies the SV2-binding site on H C A1, causing direct interference of H C A1 interaction with both the N-glycan and peptide-moiety of SV2. Interestingly, this neutralization mechanism is similar to that of a monoclonal antibody in clinical trials, despite that ciA-C2 is more than 10-times smaller. Taken together, these results enlighten our understanding of BoNT/A1 interactions with its neuronal receptor, and further demonstrate that inhibiting toxin binding to the host receptor is an efficient countermeasure strategy.
Bibliography:NIAIDOTHER
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-017-07457-5